Increased Mortality After Pulmonary Fungal Infection Within the First Year After Pediatric Lung Transplantation

Journal of Heart and Lung Transplantation

Volumn 27, Issue 6, 2008, Pages 655-661

  Danziger Isakov, Lara A ^a   Worley, Sarah ^a   Arrigain, Susana ^a   Aurora, Paul ^b   Ballmann, Manfred ^c   Boyer, Debra ^d   Conrad, Carol ^e   Eichler, Irmgard ^f   Elidemir, Okan ^g   Goldfarb, Samuel ^h   Mallory Jr , George B ^g   Michaels, Marian G ⁱ   Michelson, Peter ⁱ   Mogayzel Jr , Peter J ^j   Parakininkas, Daiva ^k   Solomon, Melinda ^l   Visner, Gary ^d   Sweet, Stuart ^m   Faro, Albert ^m  

^a LERNER RESEARCH INSTITUTE   (United States)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d HARVARD UNIVERSITY   (United States)

^e STANFORD UNIVERSITY   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g TEXAS CHILDREN S HOSPITAL   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j DEPARTMENT OF PATHOLOGY   (United States)

^k MEDICAL COLLEGE OF WISCONSIN   (United States)

^l HOSPITAL FOR SICK CHILDREN   (Canada)

^m ST LOUIS CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; ARTICLE; ASPERGILLUS; CANDIDA; CHILD; CHILDHOOD MORTALITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERFACE PRESSURE; LOG RANK TEST; LUNG ASPERGILLOSIS; LUNG GRAFT REJECTION; LUNG INFECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOSIS; PEDIATRIC SURGERY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; CHILD; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MYCOSES; PNEUMONIA; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 44149090241     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.03.010     Document Type: Article

References (40)

1. Kramer M.R., Marshall S.E., Starnes V.A., et al. Infectious complications in heart-lung transplant. Arch Intern Med 153 (1993) 2010-2016
2. Maurer J.R., Tullis D.E., Grossman R.F., et al. Infectious complications following isolated lung transplant. Chest 101 (1992) 1056-1059
3. Kanj S.S., Tapson V., Davis D.R., Madden J., and Browning I. Infections in patients with cystic fibrosis following lung transplantation. Chest 112 (1997) 924-930
4. Cahill B.C., Hibbs J.R., Savik K., et al. Aspergillus airway colonization and invasive disease in lung transplant. Chest 112 (1997) 1160-1164
5. Husni R.N., Gordon S.M., Longworth D.L., et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 26 (1998) 753-755
6. Mehrad B., Paciocco G., Martinez F.J., et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 119 (2001) 169-175
7. Minari A., Husni R., Avery R.K., et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transplant Infect Dis 4 (2002) 195-200
8. Singh N., and Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 22 (2003) 258-266
9. Westney G.E., Kesten S., deHoyos A., et al. Aspergillus infection in single lung transplant and double lung transplant recipients. Transplantation 61 (1996) 915-919
10. Ruiz I., Gavalda J., Monforte V., et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 6 (2006) 178-182
11. Helmi M., Love R.B., Welter D., Cornwell R.D., and Meyer K.C. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 123 (2003) 800-808
12. Paradowski L.J. Saprophytic fungal infections and lung transplant revisited. J Heart Lung Transplant 16 (1997) 524-531
13. Monforte V., Roman A., Gavalda J., et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 20 (2001) 1274-1281
14. Metras D., Viard L., Kreitmann B., et al. Lung infection in pediatric lung transplant: experience in 49 cases. Eur J Cardio-thorac Surg 15 (1999) 490-495
15. Kaditis A.G., Phadke S., Dickman P., et al. Mortality after pediatric lung transplantation: autopsies vs. clinical impression. Pediatr Pulmonol 37 (2004) 413-418
16. Das A., MacLaughlin E.F., Ross L.A., et al. Paecilomyces variotii in a pediatric patient with lung transplantation. Pediatr Transplant 4 (2000) 328-332
17. Hunstad D.A., Cohen A.H., and St Geme III J.W. Successful eradication of mucormycosis occurring in a pulmonary allograft. J Heart Lung Transplant 18 (1999) 801-804
18. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 (2002) 7-14
19. Pappas P.G., Andes D., Schuster M., et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 6 (2006) 386-391
20. Yousem S.A., Berry G., Brunt E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Transplant 9 (1990) 593-601
21. Yousem S.A., et al. Revision of the 1990 working formulation of the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 15 (1996) 1-15
22. Cooper J.D., Billingham M., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 12 (1993) 713-716
23. Mattner F., Chaberny I.F., Weissbrodt H., et al. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole [in German]. Mycoses 48 suppl 1 (2005) 51-55
24. Sole A., Morant P., Salavert M., Peman J., and Morales P. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11 (2005) 359-365
25. Ruffini E., Baldi S., Rapellino M., et al. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance. Sarcoid Vasc Diffuse Lung Dis 18 (2001) 181-190
26. Singhal P., Usuda K., and Mehta A.C. Post-lung transplantation Aspergillus niger infection. J Heart Lung Transplant 24 (2005) 1446-1447
27. Smith J.M., Ho P.L., and McDonald R.A. Renal transplant outcomes in adolescents: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 6 (2002) 493-499
28. Simsir A., Greenebaum E., Nuovo G., and Schulman L.L. Late fatal adenovirus pneumonitis in a lung transplant recipient. Transplantation 65 (1998) 592-594
29. Boucek M.M., Edwards L.B., Keck B.M., et al. The registry of the International Society for Heart and Lung Transplantation: sixth official pediatric report-2003. J Heart Lung Transplant 22 (2003) 636-652
30. Sudan D.L., Shaw Jr. B.W., and Langnas A.N. Causes of late mortality in pediatric liver transplant recipients. Ann Surg 227 (1998) 289-295
31. Watson A.R. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol 14 (2000) 469-472
32. Singh N., Limaye A.P., Forrest G., et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 44 (2006) 445-449
33. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377-1386
34. Duncan S.R., Paradis I.L., Yousem S.A., et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 146 (1992) 1419-1425
35. Monteforte J.S., and Wood C.A. Pneumonia caused by Nocardia nova and Aspergillus fumigatus after cardiac transplantation. Eur J Clin Microbiol Infect Dis 12 (1993) 112-114
36. Husain S., Zaldonis D., Kusne S., et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transplant Infect Dis 8 (2006) 213-218
37. Dummer J.S., Lazariashvilli N., Barnes J., Ninan M., and Milstone A.P. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 23 (2004) 1376-1381
38. Husain S., Paterson D.L., Studer S., et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 11 (2006) 2765
39. Garantziotis S., Howell D.N., McAdams H.P., et al. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 119 (2001) 1277-1280
40. Drew R.H., Dodds Ashley E., Benjamin Jr. D.K., et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 (2004) 232-237